In Re ESIP SERIES 2, LLC ( 2021 )


Menu:
  • Case: 21-164    Document: 20     Page: 1    Filed: 10/14/2021
    NOTE: This order is nonprecedential.
    United States Court of Appeals
    for the Federal Circuit
    ______________________
    In re: ESIP SERIES 2, LLC,
    Petitioner
    ______________________
    2021-164
    ______________________
    On Petition for Writ of Mandamus to the United States
    Patent and Trademark Office in No. IPR2017-02197.
    ______________________
    ON PETITION
    ______________________
    Before O’MALLEY, REYNA, and CHEN, Circuit Judges.
    REYNA, Circuit Judge.
    ORDER
    ESIP Series 2, LLC petitions this court for a writ of
    mandamus arising out of the United States Patent and
    Trademark Office (PTO)’s refusal to take up ESIP’s request
    for Director review in a closed matter. The PTO and Pu-
    zhen Life USA, LLC oppose. ESIP replies.
    Puzhen petitioned for inter partes review (IPR) of
    claims 1, 3, and 17 of ESIP’s 
    U.S. Patent No. 9,415,130
     (the
    ’130 patent). The Patent Trial and Appeal Board, acting on
    behalf of the Director, instituted as No. IPR2017-02197
    over ESIP’s objection that the petition failed to comply with
    
    35 U.S.C. § 312
    (a)(2). In its final written decision, the
    Case: 21-164    Document: 20      Page: 2    Filed: 10/14/2021
    2                                     IN RE: ESIP SERIES 2, LLC
    Board reaffirmed that conclusion. The Board further con-
    cluded that the claims were shown by Puzhen to be obvious.
    ESIP appealed the Board’s decision to this court. On
    appeal, this court affirmed the Board’s obviousness deter-
    mination. ESIP Series 2, LLC v. Puzhen Life USA, LLC,
    
    958 F.3d 1378
     (Fed. Cir. 2020). Citing Thryv, Inc. v. Click-
    to-Call Technologies, LP, 
    140 S. Ct. 1367
     (2020), this court
    further held that it was barred from reviewing the Board’s
    § 312(a)(2) determination because of 
    35 U.S.C. § 314
    (d),
    which makes the determination to institute review “final
    and nonappealable.” After the Supreme Court denied cer-
    tiorari in October 2020, the PTO issued an IPR certificate
    cancelling claims 1, 3, and 17 of the ’130 patent.
    On June 21, 2021, the Supreme Court issued its deci-
    sion in United States v. Arthrex, Inc., 
    141 S. Ct. 1970
    (2021). In Arthrex, the Court held that the IPR scheme vi-
    olates the Appointments Clause in failing to allow for a
    principal constitutional officer to review the final action of
    the administrative patent judges. The Court held that the
    proper remedy was for the Director to “review final PTAB
    decisions and, upon review, . . . issue decisions himself on
    behalf of the Board.” Arthrex, 141 S. Ct. at 1987. The PTO
    then implemented an interim rule requiring requests for
    Director review be filed within 30 days of a final written
    decision or decision on rehearing. Cf. 
    37 C.F.R. § 42.71
    (d).
    ESIP then filed a petition for Director review “of Board
    decisions in . . . [No.] IPR2017-02197” in view of Arthrex.
    Ex. 1 to ECF No. 2 at 1. ESIP received an email response
    on July 16, 2021, stating that the petition for Director re-
    view “was not filed with[in] 30 days of the entry of a final
    written decision or a decision on rehearing by a PTAB
    panel. Thus, request for Director review is untimely.” Ex.
    2 to ECF No. 2 at 1. ESIP then petitioned this court for a
    writ of mandamus to direct the Acting Director to review
    ESIP’s petition for review and to hold as unlawful the
    PTO’s 30-day deadline for requesting Director review.
    Case: 21-164     Document: 20    Page: 3    Filed: 10/14/2021
    IN RE: ESIP SERIES 2, LLC                                  3
    In response to this court’s inquiry, ESIP contends that
    it can directly appeal from the PTO’s email. We reject this
    contention. ESIP’s request was akin to a request to reopen
    or reconsider the closed IPR based on the belief that the
    Board misapplied § 312(a)(2) to the facts here and misap-
    prehended the asserted prior art. The Supreme Court has
    made clear that where, as here, such request is based
    merely on assertions of “material error”—that is, because
    it was erroneously made, not because of changed circum-
    stances or newly discovered evidence—the agency’s refusal
    to grant such request is committed to the agency’s discre-
    tion and not subject to judicial review. ICC v. Brotherhood
    of Locomotive Eng’rs, 
    482 U.S. 271
    , 280 (1987).
    We also reject ESIP’s petition to grant mandamus to
    compel the Acting Director to consider its request. Manda-
    mus is available only where the petitioner shows: (1) a clear
    and indisputable right to relief; (2) there are no adequate
    alternative legal channels to obtain that relief; and (3) the
    grant of mandamus is appropriate under the circum-
    stances. See Cheney v. U.S. Dist. Ct. for D. C., 
    542 U.S. 367
    , 380–81 (2004). ESIP has failed to satisfy that stand-
    ard here. ESIP could have raised an Appointments Clause
    challenge and sought rehearing in its prior appeal. More-
    over, ESIP has not pointed to any clear and indisputable
    authority that the PTO violated in refusing to reopen and
    rehear this particular matter, which is subject to a final
    judgment and cancellation certificate.
    Accordingly,
    IT IS ORDERED THAT:
    Case: 21-164      Document: 20   Page: 4    Filed: 10/14/2021
    4                                    IN RE: ESIP SERIES 2, LLC
    The petition is denied.
    FOR THE COURT
    October 14, 2021        /s/ Peter R. Marksteiner
    Date               Peter R. Marksteiner
    Clerk of Court
    s35
    

Document Info

Docket Number: 21-164

Filed Date: 10/14/2021

Precedential Status: Non-Precedential

Modified Date: 12/7/2021